GleamWall
中文EN

RCUS Arcus Biosciences, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1724521 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-58.3%
TTM net income YoY-32.8%
TTM EPS YoY-6.4%
Revenue 3-yr CAGR-5.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-475.0%
Net margin-453.0%
FCF margin-466.0%
EBITDA margin-465.0%

Returns

ROE-114.1%
ROA-50.6%
ROIC (approx.)-124.0%
Asset turnover0.11x

Leverage & solvency

Liabilities / assets56.2%
Debt / equity0.28x
Current ratio3.34x
Interest coverage-43.18x

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio1.3%
Payout ratio—
Capex / revenue1.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$9.00M$41.00M$17.00M$33.00M$26.00M$160.00M$28.00M$26.00M
R&D expense$117.00M$113.00M$122.00M$121.00M$141.00M$139.00M$122.00M$101.00M
SG&A expense$23.00M$24.00M$29.00M$26.00M$27.00M$29.00M$28.00M$28.00M
Operating income-$131.00M-$96.00M-$134.00M-$114.00M-$142.00M-$8.00M-$122.00M-$103.00M
Interest expense$3.00M$3.00M$3.00M$2.00M$3.00M$2.00M$1.00M$2.00M
Pretax income-$128.00M-$91.00M-$128.00M-$106.00M-$135.00M$0-$112.00M-$93.00M
Income tax$0$0$0$0$0$0$0$1.00M
Net income-$128.00M-$91.00M-$128.00M-$106.00M-$135.00M$0-$112.00M-$94.00M
EBITDA-$129.00M-$93.00M-$132.00M-$111.00M-$140.00M-$6.00M-$119.00M-$100.00M
EPS (basic)-1.00-0.72-1.02—-1.270.00-1.14—
EPS (diluted)-1.00-0.72-1.02—-1.270.00-1.14—
Weighted avg. shares (diluted)127.40M126.10M125.40M—106.50M106.50M98.40M—
Balance sheet
Cash & equivalents$151.00M$150.00M$201.00M$222.00M$238.00M$248.00M$192.00M$150.00M
Short-term investments$479.00M$552.00M$621.00M$759.00M$593.00M$663.00M$805.00M$828.00M
Current assets$664.00M$756.00M$844.00M$1.01B$857.00M$946.00M$1.03B$1.02B
PP&E, net$33.00M$36.00M$38.00M$40.00M$42.00M$44.00M$46.00M$47.00M
Total assets$818.00M$924.00M$997.00M$1.14B$974.00M$1.07B$1.16B$1.15B
Current liabilities$199.00M$198.00M$209.00M$231.00M$235.00M$210.00M$192.00M$226.00M
Long-term debt$102.00M$101.00M$100.00M$99.00M$98.00M$97.00M$48.00M$48.00M
Total debt$102.00M$101.00M$100.00M$99.00M$98.00M$97.00M$48.00M$48.00M
Total liabilities$460.00M$460.00M$473.00M$508.00M$538.00M$526.00M$625.00M$665.00M
Shareholders' equity$358.00M$464.00M$524.00M$631.00M$436.00M$549.00M$531.00M$485.00M
Net debt-$49.00M-$49.00M-$101.00M-$123.00M-$140.00M-$151.00M-$144.00M-$102.00M
Shares outstanding127.60M127.00M125.50M125.30M107.10M106.40M105.90M92.20M
Cash flow statement
Operating cash flow-$88.00M-$119.00M-$138.00M-$120.00M-$97.00M-$133.00M-$132.00M-$100.00M
Capital expenditure$0$0$0$1.00M$0$0$1.00M$1.00M
Free cash flow-$88.00M-$119.00M-$138.00M-$121.00M-$97.00M-$133.00M-$133.00M-$101.00M
Investing cash flow$82.00M$52.00M$114.00M-$182.00M$79.00M$137.00M$32.00M$51.00M
Financing cash flow$7.00M$16.00M$3.00M$286.00M$8.00M$52.00M$142.00M-$2.00M
Depreciation & amortization$2.00M$3.00M$2.00M$3.00M$2.00M$2.00M$3.00M$3.00M
Stock-based compensation$16.00M$15.00M$19.00M$15.00M$14.00M$15.00M$16.00M$17.00M

Free plan shows the latest 8 periods; Pro shows all 39 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.